| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8667879 | Journal of Cardiology | 2018 | 11 Pages |
Abstract
(1) Bivalirudin is safer than and as effective as heparin plus GPIs in CAD patients with CKD. (2) Impaired renal function does not affect the safety benefits of bivalirudin. (3) Similar efficacy profiles were identified between the two groups after both short- and long-term follow up in the CAD patients with CKD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Xiaofang MD, A. Michael MD, Stefanie MD, Philippe Gabriel MD, Yedid MSc, Roxana MD, Gregg W. MD, Thomas PhD, Jianhui MSc, Xindan MD, Wenhai MD, Han MD, Zhicheng MD, PhD, Wei MD, PhD,